Legal Representation
Attorney
G Patrick SAGE II
USPTO Deadlines
Next Deadline
2172 days remaining
Section 8 Declaration Due (Principal Register)
Due Date
January 13, 2032
Grace Period Ends
July 13, 2032
Application History
20 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Jan 13, 2026 | NRCC | E | NOTICE OF REGISTRATION CONFIRMATION EMAILED | Loading... |
| Jan 13, 2026 | R.PR | A | REGISTERED-PRINCIPAL REGISTER | Loading... |
| Nov 25, 2025 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Nov 25, 2025 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Nov 19, 2025 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Oct 27, 2025 | CNSA | O | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Oct 27, 2025 | XAEC | I | EXAMINER'S AMENDMENT ENTERED | Loading... |
| Oct 27, 2025 | GNEN | O | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | Loading... |
| Oct 27, 2025 | GNEA | F | EXAMINERS AMENDMENT E-MAILED | Loading... |
| Oct 27, 2025 | CNEA | R | EXAMINERS AMENDMENT -WRITTEN | Loading... |
| Oct 24, 2025 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Oct 24, 2025 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Oct 24, 2025 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Jul 26, 2025 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Jul 26, 2025 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Jul 26, 2025 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Jul 23, 2025 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Feb 17, 2025 | MAFR | O | APPLICATION FILING RECEIPT MAILED | Loading... |
| Feb 17, 2025 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Feb 17, 2025 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
Pharmaceutical preparations for the treatment of metabolic disorders, namely, for treating diabetes, hypoglycaemia, gout, osteoarthritis, muscular dystrophy, anemia, bulimia nervosa, anorexia, obesity and hypothyroidism; Pharmaceutical preparations for the treatment of the endocrine system, namely, for treating growth and thyroid disorders; Pharmaceutical preparations for the treatment of the musculoskeletal system, namely, for treating connective tissue diseases, bone diseases, spinal diseases, back pain, fractures, sprains, and cartilage injuries; Pharmaceutical preparations for the treatment of genitourinary diseases, namely, for treating urological diseases, infertility, sexually transmitted diseases, and inflammatory pelvic diseases; Pharmaceutical preparations for the treatment of neurological diseases, namely, for use in treating Alzheimer's disease, Huntington's disease, cerebral palsy, brain injuries, spinal cord injuries, and seizure disorders; Pharmaceutical preparations for the treatment of hormonal disorders, namely, corticosteroids, hormone replacement therapy preparations, oral contraceptives, and thyroid hormone preparations; Pharmaceutical preparations for the treatment of psychiatric diseases, namely, for treating mood disorders, anxiety disorders, cognitive disorders, schizophrenia and bipolar disorders; Pharmaceutical preparations for the treatment of cardiovascular, cardiopulmonary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, gastrointestinal, and immune system related diseases and disorders; Pharmaceutical preparations for use in dermatology, namely, for use in treating dermatitis, eczema, psoriasis, skin pigmentation diseases, and dermatological sexually transmitted diseases
Classification
International Classes
005
Disclaimers
The following terms have been disclaimed and are not claimed as part of the trademark:
Specific Disclaimer
"PHARMACEUTICALS"